Abstract
Background:
Patients with diabetes mellitus (DM) are at risk of experiencing chronic complications such as retinopathy, nephropathy and myopathy. We aimed to evaluate the effects of L-carnitine on type II DM (T2DM)-induced biochemical, contractile and pathological changes in skeletal muscles of rats.
Methods:
Thirty-two male Sprague Dawley rats were divided into the control, control+L-carnitine, T2DM and T2DM+L-carnitine groups. Plasma levels of glucose, insulin, malondialdehyde and antioxidants such as reduced glutathione, catalase and superoxide dismutase, haemoglobin A1c (HbA1c), insulin sensitivity index (ISI) as well as the contractile properties of the gastrocnemius muscle were measured. Also, histopathological studies and immunohistochemical examination of the gastrocnemius muscle using the MuRF1 (muscle RING-finger protein-1) marker were performed.
Results:
In diabetic rats, malondialdehyde, glucose, insulin, HbA1c and MuRF1 were increased, whereas ISI and antioxidants were decreased and the contractile properties deteriorated. L-carnitine decreased malondialdehyde, glucose, insulin, HbA1c and MuRF1 and increased ISI and antioxidants. Also, L-carnitine improves the contractile properties in diabetic rats. Histopathological studies confirm our data.
Conclusions:
We conclude that L-carnitine exhibits protective effects on skeletal muscles of T2DM rats through its hypoglycemic and antioxidant actions as well as its inhibitory effect on protein degradation.
Acknowledgments
The Physiology Department is acknowledged for its significant contribution to the experimental part of the study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the report for publication.
References
1. American Diabetes Association. Classification and diagnosis of diabetes. American Diabetes Association 2015;38:S8–16.10.2337/dc15-S005Search in Google Scholar PubMed
2. Arafa HM, Hemeida RA, Hassan MI, Abdel-Wahab MH, Badary OA, Hamada FM. Acetyl-L-carnitine ameliorates caerulein-induced acute pancreatitis in rats. Basic Clin Pharmacol Toxicol 2009;105:30–6.10.1111/j.1742-7843.2009.00399.xSearch in Google Scholar PubMed
3. D’Souza DM, Al-Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes mellitus on skeletal muscle progenitor cells. Front Physiol 2013;4:379.10.3389/fphys.2013.00379Search in Google Scholar PubMed PubMed Central
4. Ohlendieck K. Pathobiochemical changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics. J Nutr Metab 2012;2012, Article ID 893876, 12 pages. doi:10.1155/2012/893876.10.1155/2012/893876Search in Google Scholar PubMed PubMed Central
5. Imam KA, Sarwar M, Wali U, Siddique L, Perveen S. Gender and contractile functions of slow and fast skeletal muscles in streptozotocin induced diabetic Sprague Dawley rats. Rom J Diabetes Nutr Metab Dis 2012;19: 417–24.10.2478/v10255-012-0048-7Search in Google Scholar
6. Huang BK, Monu JU, Doumanian J. Diabetic myopathy: MRI patterns and current trends. Am J Roentgenol 2010;195:198–204.10.2214/AJR.09.2494Search in Google Scholar PubMed
7. Krishna B, Rao S, Satyanarayana M. Serum insulin levels and lipid profiles of streptozotocin induced diabetic Wistar rats. J Indian Vet Assoc 2012;10:22–6.Search in Google Scholar
8. İzgüt-Uysal VN, Ağaç A, Derin N. Effect of L-carnitine on carrageenan-induced inflammation in aged rats. Gerontology 2003;49:287–92.10.1159/000071709Search in Google Scholar PubMed
9. Onem G, Aral E, Enli Y, Oguz EO, Coskun E, Aybek H, et al. Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. J Surg Res 2006;131:124–30.10.1016/j.jss.2005.12.017Search in Google Scholar PubMed
10. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004;1033:79–91.10.1196/annals.1320.007Search in Google Scholar PubMed
11. Dokmeci D, Akpolat M, Aydogdu N, Uzal C, Doganay L, Turan FN. The protective effect of L-carnitine on ionizing radiation-induced free oxygen radicals. Scand J Lab Anim 2006;33:75–83.Search in Google Scholar
12. Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. L-carnitine and cancer cachexia: clinical and experimental aspects. J Cachexia Sarcopenia Muscle 2011;2:37–44.10.1007/s13539-011-0017-7Search in Google Scholar PubMed PubMed Central
13. Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A, Sbyrakis S. Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications 2004;18:271–4.10.1016/S1056-8727(03)00091-6Search in Google Scholar PubMed
14. Wilson RD, Islam MS. Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes. Pharmacol Rep 2012;64:129–39.10.1016/S1734-1140(12)70739-9Search in Google Scholar PubMed
15. Rajasekar P, Anuradha CV. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. Exp Diabetes Res 2007;72741.10.1155/2007/72741Search in Google Scholar PubMed PubMed Central
16. Wieland OH, Deufel T, Paetzke-Brunner I. Free and esterified carnitine: colorimetric method. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press, 1985:481–8.Search in Google Scholar
17. Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008; Article ID 704045, 9 pages. doi:10.1155/2008/704045.10.1155/2008/704045Search in Google Scholar PubMed PubMed Central
18. de Palma L, Marinelli M, Pavan M, Orazi A. Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine 2008;75:53–7.10.1016/j.jbspin.2007.04.019Search in Google Scholar PubMed
19. Stark AH, Timar B, Madar Z. Adaption of Sprague Dawley rats to long-term feeding of high fat of high fructose diets. Eur J Nutr 2000;39: 229–34.10.1007/s003940070016Search in Google Scholar PubMed
20. Salama RM, Schaalan MF, Ibrahim ME, Khalifa AE, Elkoussi AA. Effectiveness of telmisartan as an adjunct to metformin in treating type II diabetes mellitus in rats. Open J Endocr Metab Dis 2013;3:186–96.10.4236/ojemd.2013.33026Search in Google Scholar
21. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852–71.10.1016/j.cell.2012.02.017Search in Google Scholar PubMed PubMed Central
22. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902–12.10.2337/diacare.26.6.1902Search in Google Scholar PubMed
23. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944–8.10.1038/nature04634Search in Google Scholar PubMed
24. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311–20.10.1172/JCI7535Search in Google Scholar PubMed
25. Bazotte RB, Lopes-Bertolini GB. Effects of oral L-carnitine and DL-carnitine supplementation on alloxan-diabetic rats. Braz Arch Biol Technol 2012;55:81–8.10.1590/S1516-89132012000100010Search in Google Scholar
26. Kiliçli F, Dökmetas S, Candan F, Ozsahin S, Korkmaz S, Amasyali E, et al. Inspiratory muscle strength is correlated with carnitine levels in type 2 diabetes. Endocr Res 2010;35:51–8.10.3109/07435800903535506Search in Google Scholar PubMed
27. Calò LA, Vertolli U, Davis PA, Savica V. L-Carnitine in hemodialysis patients. Hemodial Int 2012;16:428–34.10.1111/j.1542-4758.2012.00679.xSearch in Google Scholar PubMed
28. Malik MO, Hussain MM, Aleem SB. Levo-carnitine normalizes blood glucose and lipid profile in insulin resistant type II diabetic rats. Pak Armed Forces Med J 2011;61:105–10.Search in Google Scholar
29. Hussein SA, Abd El-Hamid OA, Hemdan SH. Protective effect of L-carnitine on metabolic disorders, oxidative stress, antioxidant status and inflammation in a rat model of insulin resistance. Int J Biol Chem 2014;8:21–36.10.3923/ijbc.2014.21.36Search in Google Scholar
30. Shams ME, Al-Gayyar MM, Barakat EA. Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. Sci Pharm 2011;79:623–34.10.3797/scipharm.1104-21Search in Google Scholar PubMed
31. Ibrahim IM, Bastaway NA, Rateb MA, Haidara MA, Bin-Jaliah IM, Al-Hashim F, et al. Effects of insulin on ADPN and AdipoR1 in diabetic rats. Arch Med 2011;3:1–7.Search in Google Scholar
32. Abdel-Razek HA. Beneficial effect of L-carnitine on the neuromuscular performance in diabetic rats. Menoufia Med J 2010;23:159–74.Search in Google Scholar
33. Russell ST, Rajani S, Dhadda RS, Tisdale MJ. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res 2009;315:16–25.10.1016/j.yexcr.2008.10.002Search in Google Scholar PubMed
34. Fahim M, Hasan M, Alshuaib W. Early morphological remodeling of neuromuscular junction in a murine model of diabetes. J Appl Physiol 2000;89:2235–40.10.1152/jappl.2000.89.6.2235Search in Google Scholar
35. Aleem SB, Hussain MM. Levo-carnitine supplementation normalizes skeletal muscle functions in type 2 diabetic rats. Int J Diabetes Metab 2012;21:1–8.10.1159/000497719Search in Google Scholar
36. Bacurau RF, Navarro F, Bassit RA, Meneguello MO, Santos RV, Almeida AL, et al. Does exercise training interfere with the effects of L-carnitine supplementation? Nutrition 2003;19: 337–41.10.1016/S0899-9007(02)01015-8Search in Google Scholar PubMed
37. Couturier A, Ringseis R, Mooren FC, Krüger K, Most E, Eder K. Carnitine supplementation to obese Zucker rats prevents obesity-induced type II to type I muscle fiber transition and favors an oxidative phenotype of skeletal muscle. Nutr Metab 2013;10:48.10.1186/1743-7075-10-48Search in Google Scholar PubMed PubMed Central
38. Koyama S, Hata S, Witt CC, Ono Y, Lerche S, Ojima K, et al. Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J Mol Biol 2008;376:1224–36.10.1016/j.jmb.2007.11.049Search in Google Scholar PubMed
39. Keller J, Ringseis R, Priebe S, Guthke R, Kluge H, Eder K. Dietary L-carnitine alters gene expression in skeletal muscle of piglets. Mol Nutr Food Res 2011;55:419–29.10.1002/mnfr.201000293Search in Google Scholar PubMed
40. Keller J, Ringseis R, Koc A, Lukas I, Kluge H, Eder K. Supplementation with L-carnitine downregulates genes of the ubiquitin proteasome system in the skeletal muscle and liver of piglets. Animal 2012;6:70–8.10.1017/S1751731111001327Search in Google Scholar PubMed
41. Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, et al. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr 2012;31:889–95.10.1016/j.clnu.2012.03.005Search in Google Scholar PubMed
42. Hirner S, Krohne C, Schuster A, Hoffmann S, Witt S, Erber R, et al. MuRF1-dependent regulation of systemic carbohydrate metabolism as revealed from transgenic mouse studies. J Mol Biol 2008;379:666–77.10.1016/j.jmb.2008.03.049Search in Google Scholar PubMed
43. Keller J, Couturier A, Haferkamp M, Most E, Eder K. Supplementation of carnitine leads to an activation of the IGF-1/PI3K/Akt signalling pathway and down regulates the E3 ligase MuRF1 in skeletal muscle of rats. Nutr Metab 2013;10:28.10.1186/1743-7075-10-28Search in Google Scholar PubMed PubMed Central
44. Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr 2013;52:1421–42.10.1007/s00394-013-0511-0Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
